Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treating patients with geographic atrophy: are we there yet?

20 Nov 2023

Abstract excerpt

Geographic atrophy (GA) is a progressive degenerative disease that significantly contributes to visual impairment in individuals aged 50 years and older. The development of GA is influenced by various modifiable and non-modifiable risk factors, including age, smoking, and specific genetic variants, particularly those related to the complement system regulators. Given the multifactorial and complex nature of GA,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to melanin and skin pigmentation
Share to Retinal Development and Disorders
Share to Retinal Diseases and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37986170
DOI: 10.1186/s40942-023-00493-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treating patients with geographic atrophy: are we there yet?PMID 37986170Read ↗

The roadmap to geographic atrophy treatment: A journey of trials and promiseSemantic proximity Read ↗

Geographic atrophy: where we are now and where we are goingSemantic proximity Read ↗

Local Complement Inhibition for Geographic Atrophy in Age-Related Macular Degeneration: Prospects, Challenges, and Unanswered QuestionsSemantic proximity Read ↗

COMPLEMENT INHIBITION FOR GEOGRAPHIC ATROPHYSemantic proximity Read ↗

Complement cascade inhibition in geographic atrophy: a review.Semantic proximity Read ↗

Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular DegenerationSemantic proximity Read ↗

Informing Endpoints for Clinical Trials of Geographic AtrophySemantic proximity Read ↗

Real-World Outcomes with Complement Inhibitors for Geographic Atrophy: A Comparative Study of Pegacetacoplan versus Avacincaptad PegolSemantic proximity Read ↗

Complement system modulation in age-related macular degeneration: navigating failures, building future successesSemantic proximity Read ↗

Geographic Atrophy Phenotypes in Subjects of Different Ethnicity: Asia-Pacific Ocular Imaging Society Work Group Report 3.Semantic proximity Read ↗

C1q and the classical complement cascade in geographic atrophy secondary to age-related macular degenerationSemantic proximity Read ↗

Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.